Delving into the Latest Updates on Loratadine with Synapse

Overview

Basic Info

SummaryClaritin (loratadine) is a medication commonly used to treat allergies such as hay fever and hives. It belongs to the second-generation antihistamine family of medications and is taken orally. While common side effects include dry mouth, sleepiness, and headache, serious side effects such as allergic reactions, seizures, and liver problems are rare. Loratadine is generally considered safe during pregnancy, but its effects have not been well studied in this population. Children under two years of age should not take this medication. Loratadine was patented in 1980 and first became available in 1988. It is listed as an essential medication by the World Health Organization and is available as a generic. In the US, it can be purchased over the counter and was one of the most commonly prescribed medications in 2020, with over 9 million prescriptions.

Drug Type

Small molecule drug

Synonyms

Loratadine (JAN/USP/INN), Loratadine Effervescent, Loratadine Hydrochloride

+ [56]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [2]

Active Indication

Allergic skin reactionSeasonal rhinitisUpper respiratory tract allergy+ [7]

Inactive Indication

Congestion of nasal mucosa

Originator Organization

Merck & Co., Inc.

Active Organization

Shanghai Schering Plough Pharmaceutical Co. Ltd.Taro Pharmaceuticals, Inc.

Alphapharm Pty Ltd.

+ [4]

Inactive Organization

Perrigo Co. Plc

License Organization

Taisho Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Bayer Pharma AG

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (12 Apr 1993),

Rhinitis, Allergic, Seasonal

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC22H23ClN2O2

InChIKeyJCCNYMKQOSZNPW-UHFFFAOYSA-N

CAS Registry79794-75-5

A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Two-Way Crossover, Bioequivalence Study of Loratadine 5mg Chewable Tablets of AFT Pharmaceuticals, Australia Compared with Children's Claratyne® Grape 5 mg Chewable Tablets in Healthy Human Adult Subjects Under Fasting Conditions.

Start Date21 Jan 2025

Sponsor / Collaborator

AFT Pharmaceuticals Ltd.

CTRI/2024/12/077559

/ Not yet recruitingNot Applicable

An Open Label Balanced Randomized Single Dose Two Treatment Three Sequence Three Period Partial Replicate Reference Scaled Average Oral Bioequivalence Study Comparing Loratadine 1 mg/mL Oral Liquid Solution 10 X 1 mg/mL Manufactured at S Kant Healthcare Ltd for Neo Health OTC Pty Ltd with Childrens Claratyne Loratadine 1 mg/mL Peach Flavour Oral Liquid Solution Bottle 10 X 1 mg/mL Aust R 44453) distributed by Bayer Australia Ltd in Healthy Adult Human Subjects Under Fasting Conditions - NIL

Start Date16 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Loratadine

Login to view more data

100 Translational Medicine associated with Loratadine

Login to view more data

100 Patents (Medical) associated with Loratadine

Login to view more data

3,224

Literatures (Medical) associated with Loratadine

01 Jun 2025·MARINE POLLUTION BULLETIN

A robust method to quantify pharmaceuticals for the United Nations endorsed Global Estuaries Monitoring (GEM) Programme

Article

Author: Xu, Shaopeng ; Zhou, Guang-Jie ; Lai, Racliffe Weng Seng ; Chen, Chong ; Adedipe, Demilade T ; Luo, Qiong ; Brooks, Bryan W ; Leung, Kenneth Mei Yee ; Boxall, Alistair B A

Following human and animal consumption, pharmaceuticals often remain incompletely metabolized, entering aquatic ecosystems via sources like wastewater discharges, landfill leachates, and aquaculture farms, thereby eventually reaching the ocean through estuaries. This influx poses a significant threat to marine ecosystems. The Global Estuaries Monitoring (GEM) Programme, endorsed by the United Nations Decade of Ocean Science for Sustainable Development (2021-2030), aims to establish a standardized method for monitoring pharmaceuticals in the world's estuaries. This study was performed for simultaneously quantifying 65 pharmaceuticals in small-volume of water samples. The findings revealed that using 20 mL water yielded optimal recoveries between 60 % and 130 %. The influence of pH, salinity and sample matrix on the performance of the method was minimal. 45-50 pharmaceuticals remained stable over a seven-day storage period at both 4 °C and 25 °C. This cost-effective and user-friendly method paves the way for the GEM Programme to monitor pharmaceuticals in over 100 estuaries worldwide.

01 Jun 2025·MARINE POLLUTION BULLETIN

Nontargeted screening of contaminants of emerging concern in the Nandu River Estuary

Article

Author: Cao, Qingyang ; Yang, Jingjing ; Liu, He ; Li, Yihao ; Shi, Liangliang ; Deng, Yu ; Ma, Yini ; Jia, Wenhao ; Huang, Kaibo

Contaminants of emerging concern (CECs) in estuaries have received increasing attention due to their potential environmental impacts. However, detailed analyses of the sources, transport mechanisms, and environmental consequences of these contaminants remain limited. This study applied non-target screening technology to comprehensively assess CECs in the Nandu River estuary. A total of 18,000 characteristic features were screened, revealing a greater number of hydrophobic features in seawater than in the estuary. Systematic classification identified 74, 195, and 48 compounds at Levels 1, 2, and 4 respectively, with primary classifications comprising pharmaceuticals (34 %), industrial materials (23 %), pesticides (18 %), and natural products (17 %). Semi-quantitative analysis employing external standards revealed elevated concentrations of 61 monitored contaminants in estuarine zones compared to offshore waters, with Climbazole exhibiting peak concentration levels. Ecological risk assessment identified 12 contaminants of emerging concern (CECs) requiring prioritized monitoring (with RQ > 1). A priority list was established based on the frequency of detection, bioaccumulation potential, persistence, toxicity and endocrine disruption potential of the compounds. 64 CECs were identified as high priority, consisting mainly of pesticides and pharmaceutical compounds. Pesticides originate primarily from upstream agricultural activities, decreasing in concentration downstream, whereas pharmaceuticals, industrial materials, and natural products are linked to domestic sewage. Tidal cycles play a crucial role in modulating the distribution and concentration of CECs within estuarine waters. This modulation is attributed to the dynamic interaction between terrestrial inputs and coastal influences, where high tides contribute significantly to the dilution of land-derived pollutants.

01 May 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Topical loratadine-loaded invasomal gel repurposed for vulvovaginal candidiasis; in vitro, in silico, ex vivo, and in vivo studies

Article

Author: Magdy William, Mira ; Abdelmonem, Rehab ; I A Hamed, Mohammed ; Omar Rashwan, Kareem ; Darwish, Khaled M ; Ibrahim Al-Samadi, Inas Essam ; Abdellatif, Menna M

The current research work explored the anti-inflammatory and antifungal activity of loratadine versus Candida albicans for treating vulvovaginal candidiasis (VVC). Loratadine was incorporated into terpene-enriched nanocarrier invasomes (IVS) using a thin-film hydration approach, where a D-optimal design was employed to investigate the lipid amount, terpene percent and type impact on the entrapment efficiency percentage (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP). The optimal formula was assessed regarding morphology, Fourier transform infrared (FTIR), in silico study, and differential scanning calorimetry (DSC). Subsequently, the optimal formula was incorporated into a gel base and characterized via ex vivo permeation studies. Lastly, in vivo investigations were performed to evaluate the performance of the loratadine-loaded IVS gel. The selected formula was spherical and had EE% of 91.95 ± 1.5 %, PS of 132.81 ± 2.7 nm, PDI of 0.326 ± 0.08, and ZP of -23.42 ± 0.38 mV. The FTIR and DSC studies verified the successful entrapment of the drug, while the in silico study demonstrated the thermodynamic stability of IVS. The IVS gel showed enhancement in drug deposition within vaginal tissues of 3.8 folds compared to free drug gel. Loratadine-loaded IVS gel showed remarkable improvement in eradicating candida infection by suppression of β-D-glucan. Furthermore, the IVS gel showed a significant anti-inflammatory effect reflected by marked suppression of NO, iNOS, COX-2, TNF-α, IL-1B and down-regulation in NF-κB, Src and Syk gene expressions. These results were confirmed via histopathological and immunohistological examinations. This work highlights the potential of loratadine as a promising therapy for VVC.

22

News (Medical) associated with Loratadine

09 Apr 2024

·www.fiercepharma.com

Bayer taps new North America marketing chief for consumer health division

“I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol,” Samantha Avivi said in this week's announcement. In yet another C-suite shift for Bayer’s consumer health business, the division’s North America segment has appointed a new chief marketing officer. Samantha Avivi is slated to take over the role from Jeff Jarrett, Bayer announced Tuesday. Jarrett had served as marketing chief for Bayer Consumer Health’s North America region since mid-2020—a year after he joined the pharma—and is planning to retire from the company at the end of May. In a LinkedIn post Tuesday, Jarrett called his departure “truly bittersweet,” as he cited the “incredible journey” of working at Bayer while noting that “after five years at Bayer, and nearly 55 years of life, I’m ready for the next chapter… whatever it may hold!” Jarrett also congratulated Avivi on taking the reins, writing, “I’m confident her breadth of experience across so many world-class agencies and companies will bring tremendous value to our brand-building strategy and capabilities moving forward.” Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble, and at agencies including BBDO, Young & Rubicam (now part of VMLY&R) and DMB&B, prior to its acquisition by Publicis. In her new position, Avivi will spearhead North American marketing efforts for Bayer’s range of consumer brands. She’ll report to Dave Tomasi, president of Consumer Health, North America for Bayer. “I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol,” she said in the announcement. Avivi’s appointment is the latest in a spate of recent executive moves for Bayer’s consumer health department. Her new boss, Tomasi—also a Procter & Gamble alum—took on the president role just last summer, following three years as chief commercial officer for the North American consumer health segment. And earlier this year, Bayer announced a new head of the global consumer health business: Julio Triana, currently head of international commercial operations in Bayer’s pharma division, who’s set to take over the president title from Heiko Schipper on May 1. Those high-level switch-ups have taken place as Bayer continues to stave off calls for a separation of the consumer health business. During an investor day last month, CEO Bill Anderson said the company had considered selling off the division but has so far decided against it because of the sizable tax losses such a separation would bring and because the consumer health brands are still generating sold cash flow, among other reasons. This year, Bayer is expecting consumer health sales to grow between 3% and 6% while forecasting that pharma will stay flat or drop up to 4%.

Executive Change

09 Apr 2024

·www.biospace.com

Bayer’s Consumer Health Division Announces Changes to North America Leadership Team

Samantha Avivi appointed as new Chief Marketing Officer of Consumer Health, North America division. Current CMO Jeff Jarrett to retire after five years with Bayer. WHIPPANY, N.J.--(BUSINESS WIRE)-- Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer. Avivi will succeed Jeff Jarrett, who is retiring from the company at the end of May. This press release features multimedia. View the full release here: Samantha Avivi (Photo: Business Wire) “I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi. “She has expertise in setting groundbreaking visions, igniting breakthrough growth, accelerating multifunctional teams, with a proven track record of growing businesses, brands and most importantly, people.” “I also want to sincerely thank Jeff Jarrett for his dedication to the company, to our mission, and to our people,” continued Tomasi. “He’s been a driver of innovation, a champion of marketing excellence, a key leader in advancing the turnaround of our Consumer Health business, and a huge advocate for Diversity, Equity & Inclusion at Bayer. While he is leaving Bayer, the friendships he’s forged here will continue, and I wish him all the best in this exciting next chapter.” Samantha has over 25 years of client, retail and agency experience at some of the world’s largest companies like P&G, Kimberly Clark, Walmart, BBDO and Y&R. She was most recently the Chief Marketing Officer at Advance Auto Parts where she owned and executed the company’s omnichannel strategy and operations including a comprehensive marketing vision, philosophy, and plan. During her tenure, she inspired forward-looking programs in support of Advance Auto Parts and its portfolio of brands. “I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi. “I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol.” Prior to Advance Auto Parts, Samantha was the CMO at Tenneco, where she led a portfolio of 31 brands across 42 product lines in 26 countries. Samantha is a graduate of the University of Florida with a Bachelor of Business Administration (BBA). About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to bayer.com.

Executive Change

09 Jan 2024

·synapse.patsnap.com

Deciphering H1 receptor antagonists and Keeping Up with Their Recent Developments

The H1 receptor, also known as the histamine H1 receptor, plays a crucial role in the human body. It is primarily found in smooth muscle cells, endothelial cells, and nerve cells. Activation of the H1 receptor by histamine leads to various physiological responses, including vasodilation, increased vascular permeability, bronchoconstriction, and stimulation of sensory nerve endings. These responses are involved in allergic reactions, inflammation, and immune responses. Antagonists of the H1 receptor, commonly known as antihistamines, are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. Understanding the role of the H1 receptor is essential for developing effective treatments for allergic and inflammatory disorders. The analysis of the target H1 receptor reveals a competitive landscape with multiple companies actively developing drugs. GSK Plc, Sanofi, Pfizer Inc., Bayer AG, and Novartis AG are among the companies with the highest number of approved drugs or drugs in advanced stages of development. The indications with the most approved drugs include Common Cold, Rhinitis, Allergic, Urticaria, Pruritus, and Hypersensitivity. Small molecule drugs are the most rapidly progressing drug type, indicating intense competition in this area. China, the United States, and Japan are the countries with the highest number of approved drugs, with China showing significant progress in the development of drugs targeting the H1 receptor. Overall, the target H1 receptor presents opportunities for further research and development, particularly in indications with high unmet medical needs. How do they work?H1 receptor antagonists, also known as H1 blockers or antihistamines, are a class of drugs that block the action of histamine at the H1 receptor. Histamine is a chemical released by the body during an allergic reaction, causing symptoms such as itching, sneezing, runny nose, and watery eyes. H1 receptor antagonists work by binding to the H1 receptors on cells, preventing histamine from binding and exerting its effects. From a biomedical perspective, H1 receptor antagonists are commonly used to treat allergic conditions, such as hay fever (allergic rhinitis), hives (urticaria), and allergic conjunctivitis. They help alleviate symptoms by reducing the effects of histamine, thereby relieving itching, sneezing, and other allergic reactions. There are different generations of H1 receptor antagonists, each with varying degrees of sedative effects. First-generation antihistamines, such as diphenhydramine and chlorpheniramine, can cause drowsiness and are often used for their sedative properties in addition to their antihistamine effects. Second-generation antihistamines, such as cetirizine, loratadine, and fexofenadine, are less likely to cause sedation and are preferred for daytime use. In summary, H1 receptor antagonists are drugs that block the action of histamine at the H1 receptor, providing relief from allergic symptoms. They are commonly used in the treatment of various allergic conditions and come in different generations with varying sedative effects. List of H1 receptor AntagonistsThe currently marketed H1 receptor antagonists include: Olopatadine Hydrochloride/Mometasone Furoate MonohydrateChlorpheniramine Maleate/Codeine PhosphateDiphenhydramine Hydrochloride/Naproxen SodiumRecombinant interferon alfa-2b/LoratadineRupatadine FumarateAzelastine/mometasoneEbastine/Pseudoephedrine HydrochlorideAzelastine Hydrochloride/Fluticasone PropionateChlorpheniramine Maleate/Hydrocodone Bitartrate/Pseudoephedrine HydrochlorideAlcaftadineFor more information, please click on the image below. What are H1 receptor antagonists used for?H1 receptor antagonists are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. For more information, please click on the image below to log in and search. How to obtain the latest development progress of H1 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of H1 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Loratadine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00364	Loratadine	R06AX13	DB00455

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Allergic skin reaction	New Zealand	AFT Pharmaceuticals Ltd.	20 Jul 2011
Seasonal rhinitis	New Zealand	AFT Pharmaceuticals Ltd.	20 Jul 2011
Upper respiratory tract allergy	United States	Taro Pharmaceuticals, Inc.	04 Oct 2005
Perennial allergic rhinitis with seasonal variation	Australia	Alphapharm Pty Ltd.	15 Mar 2005
Respiratory Hypersensitivity	United States	Perrigo Co. Plc	24 Jun 2004
Dermatitis	Japan	Bayer Yakuhin Ltd.	27 Feb 2004
Eczema	Japan	Bayer Yakuhin Ltd.	27 Feb 2004
Urticaria	Japan	Bayer Yakuhin Ltd.	27 Feb 2004
Rhinitis, Allergic	China	Shanghai Schering Plough Pharmaceutical Co. Ltd.	01 Jan 1997
Rhinitis, Allergic	China	Bayer AG	01 Jan 1997
Chronic Urticaria	United States	Bayer Healthcare LLC	10 Oct 1996
Rhinitis, Allergic, Seasonal	United States	Bayer Healthcare LLC	12 Apr 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Congestion of nasal mucosa	Phase 3	-	Bayer AG	01 Aug 2011
Anaphylaxis	Phase 1	Germany	Bayer AG	01 Dec 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04248712 (ATEE, CTgov)	Phase 2	Eosinophilic Esophagitis	1	Famotidine+Loratadine (Treatment Group)	vzfnhmlmvl = nyrkadwagd yyqvxlfjzk (hkhwqmjrge, ouwjlcslab - atbhqovgks) View more	-	20 Dec 2022
				Placebo (Placebo Group)	ipjtsrpait(vidutnxext) = hwiafgasbl ateqkvbczo (pwngegyovo, htjpujpmfs - mhjgwxqkau) View more
NCT04162795 (CTgov)	Phase 4	Rhinitis, Allergic	468	Loratadine (Claritin, BAY76-2211)	sefpywonia = eqnrothidj nvfqdgkvrh (ccncirfdyp, mespqeilkj - usexveszec) View more	-	04 Feb 2021
ESMO_ASIA_VIRTUAL2020	Not Applicable	-	814	Loratadine	vvmsdzaefg(bwhomwjwvv) = cwzemcysfa wwnqhveqen (jrkjbwdtxa )	Negative	22 Nov 2020
				loratadine (Control)	vvmsdzaefg(bwhomwjwvv) = detbsixsxz wwnqhveqen (jrkjbwdtxa )
ASN2020	Not Applicable	Chronic Kidney Diseases	353	Allopurinol	ikzgvgqnpd(opunsbyhoq) = xthezajwfu rujwpgmtrd (vvijhzpdhj ) View more	Negative	19 Oct 2020
				Colchicine	ikzgvgqnpd(opunsbyhoq) = tgsdazwrbx rujwpgmtrd (vvijhzpdhj ) View more
NCT03855228 (C94-145, CTgov)	Phase 3	Rhinitis, Allergic, Seasonal	704	Placebo nasal spray+Loratadine (Loratadine 10 mg)	ggagvkgxtn(cqsetozeng) = pthuhjdntr yzjmspkdlc (galnwieepr, 2.2) View more	-	26 Jul 2019
				Placebo nasal spray (Placebo)	ggagvkgxtn(cqsetozeng) = chouldgufx yzjmspkdlc (galnwieepr, 2.1) View more
NCT01451996 (CTgov)	Phase 4	-	340	Claritin (Claritin Ads, Allergy+)	luhgyjxzbd(xkgcbrounb) = fditfmocpz wqivadmbzm (kxlwrixtet, 2.5) View more	-	13 Mar 2018
				Zyrtec Ads (Zyrtec Ads, Allergy+)	luhgyjxzbd(xkgcbrounb) = cnemwulplb wqivadmbzm (kxlwrixtet, 2.5) View more
NCT01311336 (Pubmed \| Support Care Cancer)	Phase 2	Ostealgia	-	Loratadine 10 mg	dumosexuhm(wjjpqsvydv) = mnfjtkgwjw dwhalwsifr (wxfzvenrmm ) View more	-	01 Jul 2016
				Placebo	dumosexuhm(wjjpqsvydv) = lyakwlnwle dwhalwsifr (wxfzvenrmm )
NCT01712009 (NOLAN, CTgov)	Phase 2	Breast Cancer \| Ostealgia	600	pegfilgrastim (No Prophylaxis)	qibsfycovd = gajewbjunf rjwsogcpwt (shopahexau, bzstnsadca - npkudojbvk) View more	-	09 Mar 2016
				Naproxen (Naproxen 500 mg BID)	qibsfycovd = pclhxofzga rjwsogcpwt (shopahexau, gqkahmlshz - asdiohdeyv) View more
NCT01469234 (P08712, CTgov)	Phase 4	Rhinitis, Allergic, Seasonal	255	placebo to fexofenadine+loratadine (Loratadine)	fwrsdxnjvi(wcmathexcd) = qorfsrwbuc xgyzgtdqub (lqmoixjsey, 4.51) View more	-	22 Mar 2013
				placebo to loratadine+fexofenadine (Fexofenadine)	fwrsdxnjvi(wcmathexcd) = ixdnngkxah xgyzgtdqub (lqmoixjsey, 4.86) View more
NCT01413958 (P08498, CTgov)	Phase 3	Rhinitis, Allergic, Seasonal \| Congestion of nasal mucosa	575	Phenylephrine+Loratadine (Phenylephrine)	bsdocuflyz(wlqkihjanb) = uoproeumim zfimjogpka (gjoleajxfi, 0.5203) View more	-	29 Jan 2013
				Placebo+Loratadine (Placebo)	bsdocuflyz(wlqkihjanb) = zcklxtqmbr zfimjogpka (gjoleajxfi, 0.5586) View more